GLP-1 Impacts on Weight Management

NCT07829016 · Not yet recruiting

Last updated 2026-09-22

This clinical trial tests how a GLP-1 medication affects weight management and disordered eating behaviors in adults with weight concerns or binge eating issues.

Status Not yet recruiting Approved but enrollment has not started.

Type Observational

Participants 100 people Planned (estimated).

Who can join Ages 12–21 · all sexes

Timeline Started 2026-09 · est. completion 2029-09

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07829016 ↗

Description as written by the study sponsor.

The goal of this observational study is to learn about the long-term effects of GLP-1RAs (Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound) in adolescents and young adults aged 12-21 who will start taking this drug for weight management. The main question it aims to answer is: How does starting GLP-1RAs impact eating behaviors and mental health symptoms? Participants starting to take GLP-1RAs as part of their medical care for weight management will answer online survey questions about their experience taking the drug for 1 year.

Main thing measured	Change in the frequency of Objective Binge Episodes
Sponsor	University of California, San Francisco
Conditions studied	Weight Management, Disordered Eating Behaviors
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07829016 ↗